Incorporating Prostacyclins Into Practice

Slides:



Advertisements
Similar presentations
Upfront Combination Therapy vs Step-Up Approach for PAH:
Advertisements

Clinical use of PAH drugs based on functional class
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Clinical Trials in IBD.
Monitoring and Modifying Treatment in PAH
Update on the Diagnosis and Management of CTEPH in Latin America
Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?
An Update on Oral Prostanoids: Advancing Care for PAH?
The Clinical Enigma of Cardiogenic Shock
UNDERSTANDING RISK STRATIFICATION IN PAH:
The Latest Data on Oral Prostacyclin Therapy in PAH
Before and After: Patient Cases in Onychomycosis
All About PAH:.
Innovative Insulin Combinations: A New strategy for the Person With T2DM.
A Closer Look at Pemphigus Vulgaris: Clinical Challenges and Emerging Treatments.
Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.
When Would You Use Single Inhaler Triple Therapy in COPD?
PAH Therapy Revisited.
PAH in Adults CHEST Guideline and Expert Panel Report: Grading of Evidence
Improving Risk Assessment and Early Diagnosis in PAH
Updates in Pulmonary Arterial Hypertension
Patient Stories: Transitioning to Oral Prostacyclin Pathway Therapy
Are We Closer to Personalized Medicine in MS?
Seizures in the Elderly: Treatment and Special Considerations
WHO Clinical Classification of PH Complex Cases in PH.
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?
Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.
Risk Assessment in PAH.
EHL Technologies in Hemophilia Care
Examining the Latest Evidence in PAH
Immunotherapy for cSCC
Introduction. Exploring Strategies for Recognition and Management of Lower Limb Spasticity in Children.
EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.
Nurse View: Practice Pearls in Advanced Pancreatic Adenocarcinoma
Oral Prostanoids and PAH
Navigating Treatment Options in PAH
Preventing Clinical Events in PAH
PAH and Prostacyclin Pathways in Focus
When Is Intrathecal Drug Delivery Appropriate?
New Horizons in Cystic Fibrosis Clinical Developments From Fall 2014
PAH-Related Morbidity as a Predictor of Mortality
PAH Treatment.
Cancer-Associated Thrombosis
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Pulmonary Arterial Hypertension and Connective Tissue Disease
Breaking News in Pemphigus Vulgaris and the Latest Updates for Your Practice.
What's New in PAH?.
PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH
Oral Prostacyclin Pathway Agents in PAH
Group 1 PAH: Current Therapies
Pulmonary Hypertension Updates From 2018
Communicating With Your Patients About Major Depressive Disorder
Improving Adherence to Antiplatelet Therapy After an ACS Event
Treating Atypical Hemolytic Uremic Syndrome A Case Discussion
Perspective on the Multidisciplinary Management of PAH
Live on PAH: Breathing Life Into Patients With PAH
Patient Stories in PAH: Sequential Therapy in a FC II Patient
Saving the Day.
Optimal Treatment of PAH
When Is Intrathecal Drug Delivery Appropriate?
Breaking Barriers in PAH: Role of Novel Early Treatment Strategies
Prostacyclin Pathway Agents in Action
Transitioning Therapy in PAH: Practical Strategies and Considerations
Incorporating New PAH Treatments Into Clinical Practice
General Principles of PH Medication Transitions
PAH Pathways: What Do the Data Tell Us?”
Pulmonary Arterial Hypertension and Hospitalizations
What's New in PAH?.
Fresh perspectives ON BASAL Insulins in diabetes care
Presentation transcript:

Incorporating Prostacyclins Into Practice

Program Goals

Therapies Targeting the Prostacyclin Pathway

Case 1 Incident Patient With Delayed Diagnosis

Risk Assessment in PAH

Treatment Algorithm for PAH

Epoprostenol for Severe PAH

Case 1 Summary

Case 2 Patient With Recent Diagnosis of PAH

Treatment Goals

Inadequate Clinical Response Subsequent Treatment Options

TRIUMPH Inhaled Treprostinil

FREEDOM Trials Oral Treprostinil

GRIPHON Selexipag

Prostacyclin Agents General Principles of Dose Titration

Prostacyclin Agents Adverse Effects

Prostacyclin Agents Strategies for Managing Dose Titration

Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)